Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Cited by 57 Publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )
Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	NHza[plHfW6ldHnvckBCe3OjeR?=	MWOwMlXDqM7:TR?=	NUjwRlBrOjRiaB?=	MWT3ZZRmeg>?	NWTxZYlwdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN?	NH;tcVQzPTF{M{C4Ni=>
Eca109	NX;SRWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUCwMlUwOi53L{Wg{txO	M3vUO\|I1NzR6L{eyJIg>	MX\3ZZRmeg>?	MofabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?=	MW[yOVEzOzB6Mh?=
Eca109	M{XVXGZ2dmO2aX;uJGF{e2G7	NWfXV3BROC53wrFOwG0>	NIrqOok3NzF{L{K0JIg>	M2jONpdifGW{	MULpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi	NXvvXph1OjVzMkOwPFI>
Eca109	M4rtNWZ2dmO2aX;uJGF{e2G7	NXvCeHpWOC53wrFOwG0>	M{HlOFI1KGh?	MUT3ZZRmeg>?	NH23cIdqdmirYnn0d{Bk\WyuIHnueoF{cW:w	MnO4NlUyOjNyOEK=
Eca109	M2PkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoD1NE42yqEQvF2=	M3;HdlI1KGh?	NFjKOpF4[XSnch?=	M3rQOYlv\HWlZYOgS\|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU>	MnG5NlUyOjNyOEK=
Eca109	M3fme2Z2dmO2aX;uJGF{e2G7	Ml3hNE42NzFizszN	MnrNNlQhcA>?	MXf3ZZRmeg>?	MoS5[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>?	MXOyOVEzOzB6Mh?=
SW1116	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jWcVAvPS9zL{KvOUDPxE1?	NX3IdXdIPDhiaB?=	NGLVWHBFVVOR	NEfHboVmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v	NWHmRnp[OjR6N{SyPFY>
LOVO	NGry[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{flb\|AvPS9zL{KvOUDPxE1?	MXW0PEBp	NYnvd5hNTE2VTx?=	Ml;l[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=>	MWeyOFg4PDJ6Nh?=
SW1116	MY\GeY5kfGmxbjDBd5NigQ>?	M2WzWVExKM7:TR?=	MWm0PEBp	MkLCSG1UVw>?	Mme0bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	MViyOFg4PDJ6Nh?=
LOVO	NYDEWJN[TnWwY4Tpc44hSXO\|YYm=	MVexNEDPxE1?	NWSzfJZSPDhiaB?=	MWLEUXNQ	NXj5OoVHcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	M4GwRlI1QDd2Mki2
SW1116	Ml[1RZBweHSxc3nzJGF{e2G7	NF\lbIIyOCEQvF2=	M3S5WlQ5KGh?	NWe2O4k4TE2VTx?=	MoS3[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz	MWeyOFg4PDJ6Nh?=
LOVO	Mk\zRZBweHSxc3nzJGF{e2G7	NEWyZWsyOCEQvF2=	MoPJOFghcA>?	M1vJVmROW09?	NX36eJNy\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{	MVmyOFg4PDJ6Nh?=
RPMI-8226	MmPMRZBweHSxc3nzJGF{e2G7	MX6xM\|Ih\|ryP	MVS0PE84Oi97NjDo	MUnEUXNQ	MoS4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M4HQWVI1QDN\|MUC4
OPM-2	Ml7vRZBweHSxc3nzJGF{e2G7	MVOxM\|Ih\|ryP	M2fTXVczNzl4L{GyNEBp	M1vV[WROW09?	Mn[1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MnXRNlQ5OzNzMEi=
JJN3	M17OTmFxd3C2b4Ppd{BCe3OjeR?=	MlXqNE42NzFizszN	NFO4SmczPC92ODDo	NWPoV415TE2VTx?=	M1TRd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	Mk\UNlQ5OzNzMEi=
NCI-H929	NGTydGdCeG:ydH;zbZMhSXO\|YYm=	MoXkNU8zKM7:TR?=	NV3ZRZhCPzJxOU[vNVIxKGh?	NWjqV2dLTE2VTx?=	M1TJTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M2jpUVI1QDN\|MUC4
RPMI-8226	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\jfmgyNzJizszN	MVqyOE81QC95MjDo	M4DBTmROW09?	M3TWbIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	M{izcVI1QDN\|MUC4
OPM-2	NX\tOIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPLNU8zKM7:TR?=	MUmyOE81QC95MjDo	M1vMSWROW09?	MVPh[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	NX7TOJY5OjR6M{OxNFg>
JJN3	M{XuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmwMlUwOSEQvF2=	MVOyOE81QC95MjDo	MUXEUXNQ	MnizZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl?	M3K0eFI1QDN\|MUC4
NCI-H929	NUDNR4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWexM\|Ih\|ryP	MXOyOE81QC95MjDo	Mk\0SG1UVw>?	NICzRZhi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	MmK3NlQ5OzNzMEi=
HeLa	M1rkS2tqdmG\|ZTDBd5NigQ>?				M4Dy[mtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE>	M4KxWFI1PzhyMEm4
HeLa	M1fVS2tqdmG\|ZTDBd5NigQ>?				MXjLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK=	NUDvc5JROjR5OECwPVg>
HeLa	NITZdVBMcW6jc3WgRZN{[Xl?				MmjJT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=>	MlrrNlQ4QDByOUi=
HeLa	NHyze4dMcW6jc3WgRZN{[Xl?				NXfJOnNKU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>?	NYL0cYhCOjR5OECwPVg>
NB4	M3\KOGZ2dmO2aX;uJGF{e2G7	M1zyfVIvPS93L{euOU8yOCEQvF2=	MYKyOEBp	Mo\BSG1UVw>?	M2LHZ4lv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE>	M1u4S\|I1PDh2OEew
CD4+ CD25− T	NH\wcmJHfW6ldHnvckBCe3OjeR?=	M3fSW\|EwPSEQvF2=			NV74SGJ3emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w	MnHENlQ1PzZ\|NkC=
BV-173	NFPtNoZCeG:ydH;zbZMhSXO\|YYm=	NWXscWhXOC5{NT:wMlUwOC55NT:xJO69VQ>?	NHXYWnI1QC95Mj:5OkBp	NX\jcXAzyqCSQmO=	NX\6S4JvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	NXy5SG9FOjR2MkO2NVM>
ML-1	NHntRnpCeG:ydH;zbZMhSXO\|YYm=	NFnMZ2YxNjJ3L{CuOU8xNjd3L{Gg{txO	NU\zWXNmPDhxN{KvPVYhcA>?	MVdCpHBDWw>?	NFfLVJBqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MYqyOFQzOzZzMx?=
HL-60	MWjBdI9xfG:\|aYOgRZN{[Xl?	NIL2e4gxNjJ3L{CuOU8xNjd3L{Gg{txO	NYHPdI1KPDhxN{KvPVYhcA>?	NFjUV\|nDqFCEUx?=	NYfyU\|dqcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	MWKyOFQzOzZzMx?=
KG-1a	MkfZRZBweHSxc3nzJGF{e2G7	MUOwMlI2NzBwNT:wMlc2NzFizszN	NUDCRWNDPDhxN{KvPVYhcA>?	MkfLxsBRSlN?	MlXObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MkDrNlQ1OjN4MUO=
BV-173	NF;NV4VHfW6ldHnvckBCe3OjeR?=	M4\2e\|I2OC93MEDuUS=>	NXn1So1TPDhiaB?=	NV\BfoZJyqCSQmO=	NVewSoN[cW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	NGLhT5UzPDR{M{[xNy=>
CEM	NYDXR3F[TnWwY4Tpc44hSXO\|YYm=	MYeyOVAwPTBybl2=	NWe4R4dbPDhiaB?=	MXpCpHBDWw>?	NITkUItqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	NHry[nozPDR{M{[xNy=>
HL-60	MlvnSpVv[3Srb36gRZN{[Xl?	MV2yOVAwPTBybl2=	NFfDc4s1QCCq	NXrYfGREyqCSQmO=	MVPpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	NWrt[\|VnOjR2MkO2NVM>
ML-1	MYTGeY5kfGmxbjDBd5NigQ>?	NHXHSWUzPTBxNUCwcm0>	MYi0PEBp	NULtXGc1yqCSQmO=	NFvhUIhqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	M1HQUFI1PDJ\|NkGz
DLD-1	MnLtSpVv[3Srb36gRZN{[Xl?	NF3XU2YzPTBxNUCwcm0>	NF7tbmw1QCCq	NX;Oc2NvyqCSQmO=	NFfwXoJldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	M33NblI1PDJ\|NkGz
HCT-116	NH;iZ21HfW6ldHnvckBCe3OjeR?=	M2PKclI2OC93MEDuUS=>	MmTQOFghcA>?	M2G1[:KhWEKV	NVPKT\|BJ\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	NFvxWnkzPDR{M{[xNy=>
U937-A/E-9/14/18	MoLSRZBweHSxc3nzJGF{e2G7	M33DVlAvODFxMD6xM\|EwOTBizszN	MXi0PEBp		NUPpb4xCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NWLhbZVkOjR\|MEC0OVY>
HT29	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3RZXN1PzJiaB?=		NHLLeodKSzVyPUG0NFDDuTF5OTFOwG0>	NFfXXoczPDF5MkC2NS=>
SW48	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX23NkBp		NETJOllKSzVyPUG1MlLDuTZwMjFOwG0>	NYDtbY9EOjRzN{KwOlE>
HCT116	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfhZZp4PzJiaB?=		NG[xSFJKSzVyPUGuO:KyOC52IN88US=>	NUH6e4VlOjRzN{KwOlE>
HepG2	M2DJcmZ2dmO2aX;uJGF{e2G7	M1z2WlAvPS9zIN88US=>	MkTUNlQhcA>?	NWW5OVNnTE2VTx?=	MlP2eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25?	MXmyOFE1Pjh5NB?=
LS174T	M3v0SGZ2dmO2aX;uJGF{e2G7	NYnseGhnOC53L{Gg{txO	MnLiNlQhcA>?	M1fQWmROW09?	NVLUTnZFdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM>	Mn\GNlQyPDZ6N{S=
HepG2	M2fBOWFxd3C2b4Ppd{BCe3OjeR?=	Mn[4NU8yOC9zMECg{txO	NY\5cppLPyCm	Mk\RSG1UVw>?	Ml[wbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NVnNTVJ1OjRzNE[4O\|Q>
LS174T	NImxdFNCeG:ydH;zbZMhSXO\|YYm=	NITMboYyNzFyL{GwNEDPxE1?	M13melch\A>?	MWPEUXNQ	NXfoe5pCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NYPLeWltOjRzNE[4O\|Q>
QBC-939	Mo[wRZBweHSxc3nzJGF{e2G7	MlK1NU8yOC9zMECg{txO	MWO3JIQ>	MX;EUXNQ	MnPSbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1T4ZVI1OTR4OEe0
U251	MXLBdI9xfG:\|aYOgRZN{[Xl?	NVPlNWhKOS9zMD:xNFAh\|ryP	M1f5S\|ch\A>?	NH7aXmdFVVOR	NEfPR5dqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M{HTc\|I1OTR4OEe0
HL-60	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDyU2cyKM7:TR?=	NXLiZmREPDhiaB?=		NEXEe4RqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?=	MmfBNlQxODB\|MkS=
MDA‑MB‑453	NFiyXYRHfW6ldHnvckBCe3OjeR?=	MYqwMlIwOSEQvF2=	NIe2T5Y4OiCq		NILiXW1k[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	NYPxUFVpOjN6NESyNlg>
HCC1569	MUXGeY5kfGmxbjDBd5NigQ>?	NWrneJZMOC5{L{Gg{txO	NWj5eJR5PzJiaB?=		NEO3PHRk[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	MWmyN\|g1PDJ{OB?=
BT‑474	NU[3fGpCTnWwY4Tpc44hSXO\|YYm=	NUnSRWVYOC5{L{Gg{txO	MX23NkBp		MWHjZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	NFvkNFUzOzh2NEKyPC=>
AGS	M3uxOmFxd3C2b4Ppd{BCe3OjeR?=	M4XOUVUwOTBxMkCvOVAh\|ryP	MlL3OFjDqGkEoB?=	MXvEUXNQ	MUTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	NEjKZWozOzV6Mke4OC=>
A549	MmGxRZBweHSxc3nzJGF{e2G7	MXG1M\|ExNzJyL{WwJO69VQ>?	NEO0T4Y1QMLiaNMg	NFX6PG1FVVOR	M{DGXolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh	MVGyN\|U5Ojd6NB?=
AGS	NG\v[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP0U3B4PS9zMD:yNE82OCEQvF2=	MofwOFjDqGkEoB?=	MmDWSG1UVw>?	MlfwbY5lfWOnczDHNk9OKHCqYYPlJIFzemW\|dNMg	NXv2N4NLOjN3OEK3PFQ>
Kasumi-1	MXvBdI9xfG:\|aYOgRZN{[Xl?	MWKwMlUh\|ryP	MXG0POKhcMLi		MoPT[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	M3TucVI{PDl\|M{S4
OCI-AML3	Moq3RZBweHSxc3nzJGF{e2G7	MV[yMlUh\|ryP	NHr3N4w1QMLiaNMg		M1LaUYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	NUHIcJBrOjN2OUOzOFg>
MV4-11	NWTtSo1USXCxcITvd4l{KEG\|c3H5	M3TTflIvPSEQvF2=	NVLqOmJFPDkEoHlCpC=>		Mn3F[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	MlT5NlM1QTN\|NEi=
NK	NUjqRY1TS3m2b4TvfIl1gSCDc4PhfS=>	MXGwMlAzNTJyIN88US=>	NEH1[FA2KGR?		MUPk[YNz\WG\|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW\|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm	NIPIT2wzOzN{OEC4PC=>
NK	MVTBdI9xfG:\|aYOgRZN{[Xl?	NVr2XZd2OC5yMj2yNEDPxE1?	NWLDeWFvPSCm		Mn[z[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl	MWKyN\|MzQDB6OB?=
NK	M2jhN2Z2dmO2aX;uJGF{e2G7	MWmwMlAyNTJyIN88US=>	MXW1JIQ>		M3nMcYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW\|cH;ud4U>	NXLhfZdjOjN\|MkiwPFg>
MOLT4/DNR	NX;yVW1jTnWwY4Tpc44hSXO\|YYm=	MljNOUDPxE1?	Mlv4OEBl		MXny[YR2[2W\|IFHCR2IyKG2UTlGg[ZhxemW\|c3nvci=>	NWfmU4VZOjNyNkC1O\|A>
Jurkat/DOX	MXjGeY5kfGmxbjDBd5NigQ>?	M3P0d\|Uh\|ryP	NVmzcHFxPCCm		MkfrdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	NGS2VYQzOzB4MEW3NC=>
MOLT4/DNR	NU\VeFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYC1JO69VQ>?	MUK0JIQ>		NV;GUm1IemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=>	NUfhfYZuOjNyNkC1O\|A>
Jurkat/DOX	M2HVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUS1JO69VQ>?	M3zFZVQh\A>?		NFflPIVz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5	M4TTOFI{ODZyNUew
ccRCC	M2S1XWFxd3C2b4Ppd{BCe3OjeR?=	M1W3fVAvODFvMUFOwG0>	M{m5cFczKGh?	M1;YbWROW09?	MVzoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	MUSyNlgzPjR4Nx?=
TNBC	MXPBdI9xfG:\|aYOgRZN{[Xl?	NWX6d45OOC5yMT2xNO69VQ>?	MX[3NkBp	M{fWRmROW09?	NYPJdFZucGG\|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?=	NHXJ[VQzOjh{NkS2Oy=>
A498	NXz6W\|hmSXCxcITvd4l{KEG\|c3H5	MnLaNE4xOS1zMN88US=>	NUnTOY9zPzJiaB?=	M2DlfGROW09?	MWfpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	MVeyNlgzPjR4Nx?=
KIJ265T	NHTFUldCeG:ydH;zbZMhSXO\|YYm=	M37OWFAvODFvMUFOwG0>	M4D6PVczKGh?	NWPtXoU3TE2VTx?=	NGnFb5ZqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	NGfyVpEzOjh{NkS2Oy=>
MDA-231	MWPBdI9xfG:\|aYOgRZN{[Xl?	NYHi[JRFOC5yMT2xNO69VQ>?	M3z5SVczKGh?	NGe5U2FFVVOR	MUPpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	NUG1[5J[OjJ6Mk[0Olc>
BT-20	NXywTmdiSXCxcITvd4l{KEG\|c3H5	NWLXeJJHOC5yMT2xNO69VQ>?	MnGzO\|IhcA>?	Ml3DSG1UVw>?	NGLTTpJqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	NYDxfmduOjJ6Mk[0Olc>
U937	NX7iUG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrMbW83PS1{MDFOwG0>	NUPZOlBlOjRxNEivO\|IhcA>?		NWPGOYJHcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	M335NlIzPzZ5MEKx
HL60	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XnUlUuOjBizszN	MnztNlQwPDhxN{KgbC=>		NVPX[Y92cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MmXZNlI4PjdyMkG=
U937	NGPvUY1CeG:ydH;zbZMhSXO\|YYm=	NFXXT5EyPSEQvF2=	NWfGOnlKOjRxNEivO\|IhcA>?		NVTPco1ocW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NFPzXlMzOjd4N{CyNS=>
HL60	MlviRZBweHSxc3nzJGF{e2G7	MXWxOUDPxE1?	M1vsNVI1NzR6L{eyJIg>		NU\HWmhycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Mn;PNlI4PjdyMkG=
LS411N	MWjBdI9xfG:\|aYOgRZN{[Xl?	MWGwMlUh\|ryP	NUf5OIloPzJiaB?=		NGDscWNqdmO{ZXHz[ZMhTmG\|IH3SUmEhdGW4ZXy=	NYT6UFVTOjJ2NkG2PVU>
MDA-MB-231	M1TUUGFxd3C2b4Ppd{BCe3OjeR?=	NWPySGgyOTBizszN	MUS0PEBp		NELzRo9z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MofJNlE5QDd4OUe=
MCF-7	MmLmRZBweHSxc3nzJGF{e2G7	NFHjZnQyOCEQvF2=	Mn33OFghcA>?		M12yUZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M{LEb\|IyQDh5Nkm3
A375	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XXdlAvPSEQvF2=	MWCxM\|UwQCCm		NXrDWol5cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NV\oPVRXOjF5OU[2NlI>
SKMEL1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGwMlUh\|ryP	NYTwT\|RsOS93L{ig[C=>		NWLaeohucW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NHnRepAzOTd7Nk[yNi=>
SKMEL3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj5e\|JEOC53IN88US=>	NF60epUyNzVxODDk		NXKzfGlScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MmrzNlE4QTZ4MkK=
SKMEL28	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWewMlUh\|ryP	NUTVfnJGOS93L{ig[C=>		NVLU[HFUcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	M2PuTVIyPzl4NkKy
MeWo	NWHuWpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnTNE42KM7:TR?=	M4racFEwPS96IHS=		MnLybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	NWfwO\|RYOjF5OU[2NlI>
B16	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXG1SnpJOC53IN88US=>	NYDxdW1{OS93L{ig[C=>		NYHWV\|hRcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MlnlNlE4QTZ4MkK=
Ly 1	M4jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUGyOEBp		MWnJR\|UxRTdwMzFOwG0>	MnPZNlE4PzJyNEm=
Ly 7	NXLPdGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{\wclI1KGh?		NGr5b5RKSzVyPUGwMlch\|ryP	NHjCe2EzOTd5MkC0PS=>
Su-DHL6	NFm3NZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLEZoYzPCCq		MnW0TWM2OO,:nkKwJO69VQ>?	MViyNVc4OjB2OR?=
Ly 10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETPXmszPCCq		NVjmVXpkUUN3MP-8olIxKM7:TR?=	MUSyNVc4OjB2OR?=
RIVA	M2PnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{fGelI1KGh?		NV3SV5lrUUN3MP-8olIxKM7:TR?=	MYiyNVc4OjB2OR?=
Su-DHL2	M1[wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVeyOEBp		M2LYcWlEPTExvK6yNEDPxE1?	M1vkXlIyPzd{MES5
Ly 1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIjpc241QCCq		NYrRZpJsUUN3ME2wMlM1KM7:TR?=	NX\BWYQ2OjF5N{KwOFk>
Ly 7	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3fTTVQ5KGh?		MV3JR\|UxRTBwMEK1JO69VQ>?	MmruNlE4PzJyNEm=
Su-DHL6	NELFW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX3WeYxJPDhiaB?=		MWLJR\|Ux97zgMkCg{txO	NX;DU4s2OjF5N{KwOFk>
Ly 10	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MonFOFghcA>?		MlfaTWM2OD1zLkig{txO	MWSyNVc4OjB2OR?=
RIVA	NXHBbYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTjOFghcA>?		MnHBTWM2OO,:nkKwJO69VQ>?	M3\qXFIyPzd{MES5
Su-DHL2	M1fK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fPTFQ5KGh?		NEnBU2VKSzVyPUG3MlQh\|ryP	MlnONlE4PzJyNEm=
Ly 1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYO3NkBp		NE\UN5FKSzVyPUCuNFEh\|ryP	NFvySVYzOTd5MkC0PS=>
Ly 7	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\NSpg4OiCq		MYDJR\|UxRTBwMEG4JO69VQ>?	NXTBeFVsOjF5N{KwOFk>
Su-DHL6	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\EVlc3PzJiaB?=		Mn;NTWM2OD1zLk[g{txO	NH2wNG0zOTd5MkC0PS=>
Ly 10	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn6zO\|IhcA>?		NXHxVlFYUUN3ME2xMlIh\|ryP	MkHONlE4PzJyNEm=
RIVA	M3Xpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX\hfXp4PzJiaB?=		MnXPTWM2OO,:nkKwJO69VQ>?	NUPjZ3lGOjF5N{KwOFk>
Su-DHL2	NU\MSFJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFT2UYo4OiCq		MoDITWM2OD1zMT6yJO69VQ>?	NXrQT2xEOjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Formulation: Decitabine is dissolved in sterile PBS . Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Deoxycytidine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Recruiting	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 9 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03828084	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals	April 17 2019	Phase 1
NCT03593915	Recruiting	Combination Product: Alvocidib Plus Decitabine	Myelodysplastic Syndromes (MDS)	Tolero Pharmaceuticals Inc.	August 29 2018	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 57 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 57 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)